Long-Term Safety of AbbVie’s HUMIRA® (adalimumab) in Immune-Related Diseases Analyzed

Long-Term Safety of Adalimumab in Immune-Related Diseases Analyzed

November 04, 2017 – Brandon May  — The use of adalimumab in arthritis and other immune-related diseases is safe and provides a favorable tolerability profile across most indications, according to findings from a study presented at the 2017 ACR/ARHP Annual Meeting held November 3-8.”

Full Source: rheumatologyadvisor.com



Leave a reply

HSAWARENESS.ORG | Fighting for Hidradenitis suppurativa (HS), a.k.a Acne Inversa Patient and Doctor Awareness ©2018 hidradenitissuppurativaawareness.org  All Rights Reserved. Your use of this website constitutes explicit agreement to our Terms of Use and Privacy Policies. This website does not provide medical advice, diagnosis or treatment.

Log in with your credentials

Forgot your details?